A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Samsung Bioepis Co., Ltd.
Study ID
NCT07524348
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • E303 — DRUG
    All participants will receive an intravenous (IV) infusion of E303

Study Details

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

Key Dates

Start date
Mar 23, 2026
Status verified
May 2026
Primary completion
Jul 31, 2030
Completion
Jul 31, 2030

Study Design

Enrollment
149 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: E303

Primary Outcome Measure

Incidence of adverse events and serious adverse events [ Time Frame: Until trial completion (estimated 3 years) ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Research SiteScottsdaleArizona85258-
Research SiteFairfaxVirginia22031-

Find similar trials in Scottsdale, AZ

By research site
Research Site· Scottsdale, AZResearch Site· Fairfax, VA

Related Studies